Openbookopenbook
Equity
Amneal Pharmaceuticals, Inc. Class A Common Stock(AMRX)
USD --+0.00%
Reward65Moderate
Risk50Moderate
📊75%Data
Thin 2% profit margin · Revenue growing 12% YoY
AMRX
+0.0 · +0.00%
USD · NASDAQ
Amneal Pharmaceuticals, Inc. Class A Common Stock | Healthcare
Growth Machine
Market Cap:4.08Bn
ℹ️
Reward Rating
65
Moderate
Top 50% (model universe)
75% data coverage
ℹ️
Risk Rating
50
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on AMRX to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $17.00.

What is Amneal Pharmaceuticals, Inc. Class A Common Stock?

, a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally.

AMRX · Verdict

Solid reward · moderate risk

AMRX stands out on valuation and growth, but watch the volatility signal.

Based on 88% data coverage

AMRX · Verdict

What’s working & what to watch

Strengths 3

  • Valuation85/100

    P/E 6.3× · PEG 0.34

  • Growth77/100

    Revenue +10.9% CAGR

  • Cash flow71/100

    9% free-cash-flow margin

Watchouts 3

  • Volatility35/100

    Below average

  • Balance sheet39/100

    Interest covered 1.6×

  • Profitability45/100

    2% net margin · -881% ROE

Model-based scoring. For information only — not financial advice.

What is Amneal Pharmaceuticals, Inc. Class A Common Stock?

, a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 4.08B, and a P/E ratio of 58.2x.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Profitability metrics are mixed — margins may be under pressure.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: Moderate (65)

The scoring profile indicates moderate reward potential, with valuation and growth as the leading contributors. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap4.08B
P/E Ratio58.1818
Dividend YieldN/A
52 Week High15.42
52 Week Low7.02
Last AnnualDecember
IPO Date1/15/2009
IncorporatedUSA
Shares Outstanding319M
No. of Employees8,700
IndustryDrug Manufacturers - Specialty & Generic
ExchangeNASDAQ
Beta1.318
CurrencyUSD
Websitewww.amneal.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.